Skip to main content
Annals of Global Health logoLink to Annals of Global Health
. 2022 Oct 21;88(1):94. doi: 10.5334/aogh.3907

Environmental Impacts on COVID-19: Mechanisms of Increased Susceptibility

Stephania A Cormier 1, Ayaho Yamamoto 2, Kirsty R Short 3, Luan Vu 1, William A Suk 4
PMCID: PMC9585976  PMID: 36348703

Abstract

Background:

Since 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in >554M cases and >6.3M deaths worldwide. The disease caused by SARS-CoV-2, COVID-19, has resulted in a broad range of clinical symptoms differing in severity. Initially, the elderly were identified as particularly susceptible to severe COVID-19, with children experiencing less severe disease. However, as new variants arise, the epidemiology of SARS-CoV-2 infection is changing, and the disease severity in children is increasing. While environmental impacts on COVID-19 have been described, the underlying mechanisms are poorly described.

Objective:

The Pacific Basin Consortium for Environment and Health (PBC) held meeting on September 16, 2021, to explore environmental impacts on infectious diseases, including COVID-19.

Methods:

The PBC is an international group of environmental scientists and those interested in health outcomes. The PBC met to present preliminary data and discuss the role of exposures to airborne pollutants in enhancing susceptibility to and severity of respiratory tract viral infections, including COVID-19.

Findings:

Analysis of the literature and data presented identified age as an important factor in vulnerability to air pollution and enhanced COVID-19 susceptibility and severity. Mechanisms involved in increasing severity of COVID-19 were discussed, and gaps in knowledge were identified.

Conclusions:

Exposure to particulate matter (PM) pollution enhanced morbidity and mortality to COVID-19 in a pediatric population associated with induction of oxidative stress. In addition, free radicals present on PM can induce rapid changes in the viral genome that can lead to vaccine escape, altered host susceptibility, and viral pathogenicity. Nutritional antioxidant supplements have been shown to reduce the severity of viral infections, inhibit the inflammatory cytokine storm, and boost host immunity and may be of benefit in combating COVID-19.

Keywords: COVID 19, air pollution, respiratory viral infections, age

Age and Susceptibility to SARS-CoV-2 Infection

Children typically experience more mild symptoms of COVID-19 when compared to adults. There is a strong body of evidence that children are found to be less susceptible to SARS-CoV-2 infection with the original Wuhan isolate. The reasons for reduced SARS-CoV-2 symptoms and infection in children remain unclear and may be influenced by a multitude of factors, including differences in target cell susceptibility and innate immune responses [1]. Using primary nasal epithelial cells from children and adults, differentiated at an air-liquid interface (ALI) we showed that SARS-CoV-2 (both the Wuhan isolate and the more recent Alpha variant) replicate to significantly lower titers in the nasal epithelial cells of children compared to those of adults [2]. This was associated with a heightened antiviral response to SARS-CoV-2 in the nasal epithelial cells of children. Importantly, influenza virus, a virus whose transmission is frequently associated with pediatric infections, replicated in both adult and pediatric nasal epithelial cells to comparable titers. We have expanded these data to show that the more recent Delta, but not Omicron variant also replicated less in children’s nasal cells [2]. Taken together, these data show that the nasal epithelium of children supports lower infection and replication of the earlier SARS-CoV-2 variants than the adult nasal epithelium. Why viral replication is increased in children with the more recent Omicron variants is not known, but it is consistent with the epidemiology showing an increased number of cases in children as these have become dominant [3]. Traffic-related air pollution exposure during childhood is associated with an increased risk of severe respiratory infections [4,5]. However, the interplay between age, environment, and COVID-19 remains unclear.

Areas of High Particulate Pollution and COVID

As with other viruses, epidemiological data demonstrate a strong influence of environmental factors on the incidence of infection with SARS-CoV-2 and the severity of COVID-19. Areas with high particulate matter (PM) pollution have been associated with increased mortality, not only to SARS-CoV-1 but recently to SARS-CoV-2 [6,7], compared to regions with lower air pollution. The air pollution index (API), which is a simplified way to describe air quality and incorporates carbon monoxide, ozone, nitrogen dioxide, sulfur dioxide, and PM2.5 was used in this study; and a moderate API of 51–100 was associated with an 84% increased mortality risk. Long-term and historical exposure to elevated PM2.5 levels have also been associated with a significant increase in COVID mortality. Specifically, an increase of 1 µg/m3 in the long-term average PM2.5 level correlated with an 11% increase in the COVID mortality rate [7]. The increase in mortality was even greater among black individuals. These data are reviewed in more detail in a companion paper in this series [8].

Several theories exist to explain the role of PM in enhanced morbidity and mortality of COVID-19. The first is that PM acts as a carrier for the virus - hijacking a ride on airborne PM. This has been demonstrated with other pathogens, including bacteria, fungi, and viruses [9,10,11,12], and most recently demonstrated for SARS-CoV-2 [11,13]. It has been further hypothesized that the hijacked particle could enhance viral persistence and respirability, allowing it access to the lower airways. While ambient sources of PM2.5 vary between locations, combustion and industrial emissions are the major producers, and PM2.5 from such sources typically are associated with environmentally persistent free radicals (EPFRs) [14,15]. We further posit that the presence of EPFRs on PM can: 1) damage the airways inducing an immunosuppressive pulmonary microenvironment as has been demonstrated with influenza [16,17,18]; 2) induce mutations in the viral genome, increasing infectivity and/or pathogenicity of the virus; and/or 3) oxidize surface molecules on the virus altering the ability of the immune system to recognize the virus (Figure 1).

Figure 1.

Potential roles of EPFRs in enhancing viral morbidity and mortality

Potential roles of EPFRs in enhancing viral morbidity and mortality.

The first two hypotheses were explored using well-differentiated human nasal epithelial cells cultured at ALI (Ethics approval: No.#UQ2017000520; HREC61894; UQ2020001742), and preliminary data presented demonstrates that exposure to moderate level of EPFRs impaired epithelial barrier and reduced mucus production. Decreasing mucus production removes part of the first-line defense of respiratory epithelial cells and would be expected to increase viral access to the cell surface receptors.

Supernatants containing SARS-CoV-2 viral particles from these same ALI cultures were isolated, and genetic modifications were identified by sequencing. Significant increases in the number of nucleotide changes were observed from ALIs exposed to EPFRs (i.e., a 33% increase compared to control air-exposed ALIs) for as short as 24h. While changes were observed across the genome, the largest number of changes were observed in the S gene, which codes for the Spike protein, followed by the E gene, which codes the Envelope protein. Intriguingly, mutations were observed at the N-terminal domain (NTD) of the S1 subunit and at S1/S2 cleavage site (Figure 2).

Figure 2.

The SARS-CoV-2 NTD comprised multiple mutation following EPFR exposure

The SARS-CoV-2 NTD comprised multiple mutation at 48 and 72h post EPFR exposure. Mutations are highlighted as yellow spheres.

While the receptor binding domain of S1 mediates viral infection by binding to host ACE2 receptors and is recognized as the key target for neutralization antibodies, the target of NTD is still unknown [19]. Still, changes in the conformation of exposed NTD loops have been associated with increased infectivity [20].

Furthermore, many potential neutralizing antibodies targeting NTD have been identified [21,22]. These NTD-targeting antibodies target supersite epitopes harbored at the most exposed region of NTD (spanning from amino acid position 24 to 333) and have been shown to neutralize SARS-CoV-2 in vitro and in vivo [21,23,24]. Thus, our preliminary data suggest that exposure to EPFRs can alter viral infectivity and affect an immune escape. Considering the significance of pollution exposure-mediated viral respiratory diseases, we urge future studies to further investigate and empirically validate our current findings.

While it is generally recognized that alterations in the S protein could alter infectivity and impact host protection (both in terms of immune evasion and vaccine escape), the role of genetic alterations in the E protein is less understood. The E protein is important in viral assembly, budding, and pathogenesis via damage to epithelial tight junctions [25]; alterations here may thus be critical in altering morbidity.

Oxidative stress plays an important role in environmental exposure and viral infections [26,27]. When SARS-CoV-2 enters cells, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is activated, resulting in increased mitochondrial reactive oxygen species (mtROS) [28] and EPFR exposure also increases mtROS [29]. Thus, excessive production of mtROS induced by air pollution may result in oxidative stress in epithelial cells, which might be one of the key mechanisms increasing severity of COVID-19.

Infections and environmental exposure can trigger cytokine secretion as a host defense [30]. Exaggerated secretion of cytokines by both airway epithelium and immune cells such as macrophages, T cells, and neutrophils can cause organ failure and increase the severity of COVID-19 [31]. Severe COVID-19 can include ‘cytokine storm syndrome’ because of uncontrolled immune responses [32]. Both EPFR exposure and SARS-CoV-2 infection increased the pro-inflammatory cytokine, tumour necrosis factor α (TNF-α) production [29,33]. Massive accumulation of TNF-α can contribute to cytokine storm; acute lung injury, or acute respiratory distress syndrome [34,35].

PM induces oxidative stress and inflammation, and this can further enhance SARS-CoV-2-induced inflammation resulting in reduced therapeutic efficiency [24]. Multiple nutritional antioxidant supplements have been shown to reduce the severity of viral infections, inhibit the inflammatory cytokine storm, and boost host immunity [36]. Thus, those nutritional compounds may benefit COVID-19 treatment. Several clinical trials for antioxidant treatment for COVID-19 have been conducted, and some of them are still ongoing [37]. Two doses of N-acetylcysteine (NAC), a well-known antioxidant, did not decrease COVID-19 severity [38]; but a mixture of methylene blue, Vitamin C and NAC treatment increased the survival rate in severe COVID-19 patients [35]. Single antioxidant agents have not shown promising results in clinical trials. Alternative agents with better antioxidant capacity or combinations of antioxidants might be a better option for treating COVID-19.

Conclusion

Direct evidence, in a human system, of the mechanisms by which environmental pollutants, including EPFRs increase susceptibility for respiratory tract viral infections, including COVID-19, is needed. Further, identification of methods to reduce pollutant-mediated susceptibility using readily available therapies will be of great benefit. The significance of some of the data presented comes from the potential to reduce susceptibility to respiratory tract viral infections in the billions of people globally who are exposed to EPFRs from combustion and industrial processes. Finally, it is anticipated that resulting data will be essential to guide policy related to future pandemics.

Acknowledgements

The current work was supported by grants awarded to Dr. Stephania A Cormier from the National Institutes of Health (R01AI090059, R01ES015050, P42ES013648, and U13ES033440-01).

Funding Statement

The current work was supported by grants awarded to Dr. Stephania A Cormier from the National Institutes of Health (R01AI090059, R01ES015050, P42ES013648, and U13ES033440-01).

Abbreviations

ALI – air-liquid interface

API – air pollution index

PM – Particulate Matter

EPFR – Environmentally persistent free radicals

NAC – N-acetylcysteine

ROS – reactive oxygen species

SARS-CoV-2 – severe acute respiratory syndrome coronavirus 2

TNF-α – tumour necrosis factor α

Competing Interests

The authors have no competing interests to declare.

References

  • 1.Sly PD, Trottier BA, Bulka CM, Cormier SA, Fobil J, Fry RC, et al. The interplay between environmental exposures and COVID-19 risks in the health of children. Environmental Health. 2021; 20(1): 34. DOI: 10.1186/s12940-021-00716-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Zhu Y, Chew KY, Wu M, Karawita AC, McCallum G, Steele LE, et al. Ancestral SARS-CoV-2, but not Omicron, replicates less efficiently in primary pediatric nasal epithelial cells. PLos Biology. 2022; In press. DOI: 10.1371/journal.pbio.3001728 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Belay ED, Godfred-Cato S. SARS-CoV-2 spread and hospitalisations in paediatric patients during the omicron surge. Lancet Child Adolesc Health. 2022; 6(5): 280–1. DOI: 10.1016/S2352-4642(22)00060-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Goldizen FC, Sly PD, Knibbs LD. Respiratory effects of air pollution on children. Pediatr Pulmonol. 2015; 51: 94–108. DOI: 10.1002/ppul.23262 [DOI] [PubMed] [Google Scholar]
  • 5.Stern G, Latzin P, Roosli M, Fuchs O, Proietti E, Kuehni C, et al. A prospective study of the impact of air pollution on respiratory symptoms and infections in infants. Am J Respir Crit Care Med. 2013; 187(12): 1341–8. DOI: 10.1164/rccm.201211-2008OC [DOI] [PubMed] [Google Scholar]
  • 6.Cui Y, Zhang Z-F, Froines J, Zhao J, Wang H, Yu S-Z, et al. Air pollution and case fatality of SARS in the People’s Republic of China: an ecologic study. Environmental Health. 2003; 2(1): 15. DOI: 10.1186/1476-069X-2-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Wu X, Nethery RC, Sabath MB, Braun D, Dominici F. Air pollution and COVID-19 mortality in the United States: Strengths and limitations of an ecological regression analysis. Science Advances. 2020; 6(45): eabd4049. DOI: 10.1126/sciadv.abd4049 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Sly PD, Trottier B, Ikeda-Araki A, Vilcins D. Environmental impacts on infectious disease: a literature view of epidemiological evidence. Annals of Global Health. 2022; In Press. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Gloster J, Alexandersen S. New directions: Airborne transmission of foot-and-mouth disease virus. Atmospheric Environment. 2004; 38(3): 503–5. DOI: 10.1016/j.atmosenv.2003.10.014 [DOI] [Google Scholar]
  • 10.Sedlmaier N, Hoppenheidt K, Krist H, Lehmann S, Lang H, Buttner M. Generation of avian influenza virus (AIV) contaminated fecal fine particulate matter (PM2.5): Genome and infectivity detection and calculation of immission. Veterinary Microbiology. 2009; 139(1–2): 156–64. DOI: 10.1016/j.vetmic.2009.05.005 [DOI] [PubMed] [Google Scholar]
  • 11.Setti L, Passarini F, De Gennaro G, Barbieri P, Perrone MG, Borelli M, et al. SARS-Cov-2RNA found on particulate matter of Bergamo in Northern Italy: First evidence. Environmental Research. 2020; 188. DOI: 10.1016/j.envres.2020.109754 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020; 584(7821): 450–6. DOI: 10.1038/s41586-020-2571-7 [DOI] [PubMed] [Google Scholar]
  • 13.Pivato A, Amoruso I, Formenton G, Di Maria F, Bonato T, Vanin S, et al. Evaluating the presence of SARS-CoV-2 RNA in the particulate matters during the peak of COVID-19 in Padua, northern Italy. Science of The Total Environment. 2021; 784: 147129. DOI: 10.1016/j.scitotenv.2021.147129 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Kennedy IM. The health effects of combustion-generated aerosols. Proceedings of the Combustion Institute. 2007; 31: 2757–70. DOI: 10.1016/j.proci.2006.08.116 [DOI] [Google Scholar]
  • 15.Cass GR, Hughes LA, Bhave P, Kleeman MJ, Allen JO, Salmon LG. The chemical composition of atmospheric ultrafine particles. Philosophical Transactions of the Royal Society a-Mathematical Physical and Engineering Sciences. 2000; 358(1775): 2581–92. DOI: 10.1098/rsta.2000.0670 [DOI] [Google Scholar]
  • 16.Jaligama S, Saravia J, You D, Yadav N, Lee GI, Shrestha B, et al. Regulatory T cells and IL10 suppress pulmonary host defense during early-life exposure to radical containing combustion derived ultrafine particulate matter. Respir Res. 2017; 18(1): 15. DOI: 10.1186/s12931-016-0487-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Lee GI, Saravia J, You D, Shrestha B, Jaligama S, Hebert VY, et al. Exposure to combustion generated environmentally persistent free radicals enhances severity of influenza virus infection. Part Fibre Toxicol. 2014; 11: 57. DOI: 10.1186/s12989-014-0057-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Saravia J, Lee GI, Lomnicki S, Dellinger B, Cormier SA. Particulate matter containing environmentally persistent free radicals and adverse infant respiratory health effects: a review. J Biochem Mol Toxicol. 2013; 27(1): 56–68. DOI: 10.1002/jbt.21465 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nature Reviews Microbiology. 2021; 19(7): 409–24. DOI: 10.1038/s41579-021-00573-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Meng B, Kemp SA, Papa G, Datir R, Ferreira IATM, Marelli S, et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Reports. 2021; 35(13): 109292. DOI: 10.1016/j.celrep.2021.109292 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.McCallum M, De Marco A, Lempp FA, Tortorici MA, Pinto D, Walls AC, et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell. 2021; 184(9): 2332–47.e16. DOI: 10.1016/j.cell.2021.03.028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Scientific Reports. 2021; 11(1): 4263. DOI: 10.1038/s41598-021-82862-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020; 369(6504): 650–5. DOI: 10.1126/science.abc6952 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020; 146(1): 110–8. DOI: 10.1016/j.jaci.2020.04.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Shepley-McTaggart A, Sagum CA, Oliva I, Rybakovsky E, DiGuilio K, Liang J, et al. SARS-CoV-2 Envelope (E) protein interacts with PDZ-domain-2 of host tight junction protein ZO1. PLOS ONE. 2021; 16(6): e0251955. DOI: 10.1371/journal.pone.0251955 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Camini FC, da Silva Caetano CC, Almeida LT, de Brito Magalhães CL. Implications of oxidative stress on viral pathogenesis. Arch Virol. 2017; 162(4): 907–17. DOI: 10.1007/s00705-016-3187-y [DOI] [PubMed] [Google Scholar]
  • 27.Boukhenouna S, Wilson MA, Bahmed K, Kosmider B. Reactive Oxygen Species in Chronic Obstructive Pulmonary Disease. Oxid Med Cell Longev. 2018; 2018: 5730395. DOI: 10.1155/2018/5730395 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Chang R, Mamun A, Dominic A, Le NT. SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress. Front Physiol. 2020; 11: 605908. DOI: 10.3389/fphys.2020.605908 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Harmon AC, Hebert VY, Cormier SA, Subramanian B, Reed JR, Backes WL, et al. Particulate matter containing environmentally persistent free radicals induces AhR-dependent cytokine and reactive oxygen species production in human bronchial epithelial cells. PLoS One. 2018; 13(10): e0205412. DOI: 10.1371/journal.pone.0205412 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Iwasaki A, Foxman EF, Molony RD. Early local immune defences in the respiratory tract. Nat Rev Immunol. 2017; 17(1): 7–20. DOI: 10.1038/nri.2016.117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Chen H, Liu W, Wang Y, Liu D, Zhao L, Yu J. SARS-CoV-2 activates lung epithelial cell proinflammatory signaling and leads to immune dysregulation in COVID-19 patients. EBioMedicine. 2021; 70: 103500. DOI: 10.1016/j.ebiom.2021.103500 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, et al. On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis Rheumatol. 2020; 72(7): 1059–63. DOI: 10.1002/art.41285 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P, et al. Synergism of TNF-alpha and IFN-gamma Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. Cell. 2021; 184(1): 149–68 e17. DOI: 10.1016/j.cell.2020.11.025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Shimizu M. Clinical Features of Cytokine Storm Syndrome. In: Cron RQ, Behrens EM (eds.), Cytokine Storm Syndrome. Cham: Springer International Publishing. 2019; 31–41. DOI: 10.1007/978-3-030-22094-5_3 [DOI] [Google Scholar]
  • 35.Alamdari DH, Moghaddam AB, Amini S, Keramati MR, Zarmehri AM, Alamdari AH, et al. Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial. Eur J Pharmacol. 2020; 885: 173494. DOI: 10.1016/j.ejphar.2020.173494 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Mrityunjaya M, Pavithra V, Neelam R, Janhavi P, Halami PM, Ravindra PV. Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19. Front Immunol. 2020; 11: 570122. DOI: 10.3389/fimmu.2020.570122 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Beigmohammadi MT, Bitarafan S, Hoseindokht A, Abdollahi A, Amoozadeh L, Mahmoodi Ali Abadi M, et al. Impact of vitamins A, B, C, D, and E supplementation on improvement and mortality rate in ICU patients with coronavirus-19: a structured summary of a study protocol for a randomized controlled trial. Trials. 2020; 21(1): 614. DOI: 10.1186/s13063-020-04547-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.de Alencar JCG, Moreira CL, Müller AD, Chaves CE, Fukuhara MA, da Silva EA, et al. Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. 2021; 72(11): e736–e41. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of Global Health are provided here courtesy of Ubiquity Press

RESOURCES